Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Allogene Therapeutics, Inc.ALLO · Entity 5243 | SVP, Finance | April 21, 2026 | April 23, 2026 |
| Tricida, Inc.TCDA · Entity 122050 | Senior VP, Finance and CAO | August 05, 2022 | August 09, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Allogene Therapeutics, Inc.
Report date April 21, 2026 · Filed April 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 124,517 |
Reported balance
After 2026-04-21 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-04-21 · Sale · Disposed 9,586 · Balance 124,517 F1: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $2.31 to $2.33, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F3: Includes 3,781 shares of the Issuer's common stock acquired by the reporting person on March 15, 2026 pursuant to an employee stock purchase program. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $2.31 to $2.33, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F3: Includes 3,781 shares of the Issuer's common stock acquired by the reporting person on March 15, 2026 pursuant to an employee stock purchase program.
Tricida, Inc.
Report date August 05, 2022 · Filed August 09, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.86 · Expires 2032-08-04 | Direct | 14,000 |
Reported balance
After 2022-08-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-08-05 · Grant · Acquired 14,000 · Balance 14,000 F1: The option to purchase common stock will vest as follows: (a) 25% of the shares subject to the options shall vest on August 5, 2023 and (b) the remaining 75% vest in 36 equal monthly installments thereafter, subject to reporting person's continuous service as of each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option to purchase common stock will vest as follows: (a) 25% of the shares subject to the options shall vest on August 5, 2023 and (b) the remaining 75% vest in 36 equal monthly installments thereafter, subject to reporting person's continuous service as of each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 21, 2026 Filed Apr 23, 2026 20:16 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 9,586 | $2.31 | $22,143.66 |
DisclosureSEC source: 0001835208-26-000003 · wk-form4_1776975369.xml · nonDerivative · entry 1 Yoshiyama Annie · CIK 0001835208 · SVP, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,517 F1 · shares: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $2.31 to $2.33, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · balance_after: Includes 3,781 shares of the Issuer's common stock acquired by the reporting person on March 15, 2026 pursuant to an employee stock purchase program. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 22:09 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantRestricted Stock Unit · Derivative | 50,827 | $0.00 | $0.00 |
DisclosureSEC source: 0001737287-26-000005 · wk-form4_1770242977.xml · derivative · entry 3 Yoshiyama Annie · CIK 0001835208 · SVP, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,827 Underlying: Common Stock · 50,827 shares Expires not disclosed F5 · derivative.exercise_price: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal annual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date. F5 · derivative.exercise_date: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal annual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date. F5 · derivative.expiration_date: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal annual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 22:09 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantStock Option (Right to buy) · Derivative | 179,691 | $0.00 Strike: $1.87 | $0.00 |
DisclosureSEC source: 0001737287-26-000005 · wk-form4_1770242977.xml · derivative · entry 2 Yoshiyama Annie · CIK 0001835208 · SVP, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,691 Underlying: Common Stock · 179,691 shares Expires 2036-02-02 F4 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on February 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 22:09 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 4,167 | $1.72 | $7,167.24 |
DisclosureSEC source: 0001737287-26-000005 · wk-form4_1770242977.xml · nonDerivative · entry 1 Yoshiyama Annie · CIK 0001835208 · SVP, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,322 F1 · shares: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $1.71 to $1.74, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · balance_after: Includes 3,826 shares of the Issuer's common stock acquired by the reporting person on September 15, 2025 pursuant to an employee stock purchase program. Read SEC document |
| April 21, 2025 Filed Apr 23, 2025 21:28 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 9,601 | $1.41 | $13,537.41 |
DisclosureSEC source: 0001835208-25-000007 · wk-form4_1745443726.xml · nonDerivative · entry 1 Yoshiyama Annie · CIK 0001835208 · SVP, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,663 F1 · shares: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plant to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Includes 2274 shares of the Issuer's common stock acquired by the reporting person on March 14, 2025 pursuant to an employee stock purchase program. Read SEC document |
| January 24, 2025 Filed Jan 29, 2025 01:14 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantStock Option (Right to buy) · Derivative | 128,093 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0001737287-25-000007 · wk-form4_1738113240.xml · derivative · entry 2 Yoshiyama Annie · CIK 0001835208 · SVP, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,093 Underlying: Common Stock · 128,093 shares Expires 2035-01-24 F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on January 24, 2026, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| January 24, 2025 Filed Jan 29, 2025 01:14 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantCommon Stock | 36,232 | $0.00 | $0.00 |
DisclosureSEC source: 0001737287-25-000007 · wk-form4_1738113240.xml · nonDerivative · entry 1 Yoshiyama Annie · CIK 0001835208 · SVP, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,990 Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 16:22 UTC | Tricida, Inc. TCDA · Entity 122050 | GrantEmployee Stock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $10.86 | $0.00 |
DisclosureSEC source: 0001595585-22-000069 · wf-form4_166007654061166.xml · derivative · entry 1 Yoshiyama Annie · CIK 0001835208 · Senior VP, Finance and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2032-08-04 F1 · derivative.exercise_date: The option to purchase common stock will vest as follows: (a) 25% of the shares subject to the options shall vest on August 5, 2023 and (b) the remaining 75% vest in 36 equal monthly installments thereafter, subject to reporting person's continuous service as of each vesting date. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 16:55 UTC | Tricida, Inc. TCDA · Entity 122050 | GrantEmployee Stock Option (right to buy) · Derivative | 86,000 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0001595585-22-000018 · wf-form4_164625812252886.xml · derivative · entry 1 Yoshiyama Annie · CIK 0001835208 · VP, Finance and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,000 Underlying: Common Stock · 86,000 shares Expires 2032-02-27 F1 · derivative.exercise_date: The option to purchase common stock will vest as follows: (a) 25% of the shares subject to the options shall vest on February 28, 2023, and (b) the remaining 75% vest in 36 equal monthly installments thereafter, subject to reporting person's continuous service as of each vesting date. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 16:11 UTC | Tricida, Inc. TCDA · Entity 122050 | GrantEmployee Stock Option (right to buy) · Derivative | 2,747 | $0.00 Strike: $3.88 | $0.00 |
DisclosureSEC source: 0001595585-21-000109 · wf-form4_162931748837848.xml · derivative · entry 11 Yoshiyama Annie · CIK 0001835208 · VP, Finance and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,747 Underlying: Common Stock · 2,747 shares Expires 2028-08-15 F10 · price: On August 16, 2021, the issuer canceled, pursuant to the issuer's stock option exchange program, an option granted to the reporting person on February 24, 2020. In exchange for the option, the reporting person received two stock options in the amounts of 1,506 and 2,747. F4 · derivative.exercise_date: This option vests one-third on August 16, 2022 and the remaining two-thirds vests in 24 substantially equal monthly installments thereafter, subject to reporting person's continuous service as of each vesting date. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 16:11 UTC | Tricida, Inc. TCDA · Entity 122050 | GrantEmployee Stock Option (right to buy) · Derivative | 1,506 | $0.00 Strike: $3.88 | $0.00 |
DisclosureSEC source: 0001595585-21-000109 · wf-form4_162931748837848.xml · derivative · entry 10 Yoshiyama Annie · CIK 0001835208 · VP, Finance and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,506 Underlying: Common Stock · 1,506 shares Expires 2028-08-15 F10 · price: On August 16, 2021, the issuer canceled, pursuant to the issuer's stock option exchange program, an option granted to the reporting person on February 24, 2020. In exchange for the option, the reporting person received two stock options in the amounts of 1,506 and 2,747. F3 · derivative.exercise_date: This option vests on August 16, 2022. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 16:11 UTC | Tricida, Inc. TCDA · Entity 122050 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 10,630 | $0.00 Strike: $35.12 | $0.00 |
DisclosureSEC source: 0001595585-21-000109 · wf-form4_162931748837848.xml · derivative · entry 9 Yoshiyama Annie · CIK 0001835208 · VP, Finance and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,630 shares Expires 2030-02-23 F10 · price: On August 16, 2021, the issuer canceled, pursuant to the issuer's stock option exchange program, an option granted to the reporting person on February 24, 2020. In exchange for the option, the reporting person received two stock options in the amounts of 1,506 and 2,747. F9 · derivative.exercise_date: This cancelled option vested 25% on February 24, 2021, and the remaining 75% vests in 36 substantially equal monthly installments thereafter, subject to reporting person's continuous service as of each vesting date. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 16:11 UTC | Tricida, Inc. TCDA · Entity 122050 | GrantEmployee Stock Option (right to buy) · Derivative | 1,600 | $0.00 Strike: $3.88 | $0.00 |
DisclosureSEC source: 0001595585-21-000109 · wf-form4_162931748837848.xml · derivative · entry 8 Yoshiyama Annie · CIK 0001835208 · VP, Finance and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,600 Underlying: Common Stock · 1,600 shares Expires 2028-08-15 F8 · price: On August 16, 2021, the issuer canceled, pursuant to the issuer's stock option exchange program, an option granted to the reporting person on August 22, 2019. In exchange for the option, the reporting person received 1,600 stock options. F3 · derivative.exercise_date: This option vests on August 16, 2022. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 16:11 UTC | Tricida, Inc. TCDA · Entity 122050 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $34.27 | $0.00 |
DisclosureSEC source: 0001595585-21-000109 · wf-form4_162931748837848.xml · derivative · entry 7 Yoshiyama Annie · CIK 0001835208 · VP, Finance and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2029-08-21 F8 · price: On August 16, 2021, the issuer canceled, pursuant to the issuer's stock option exchange program, an option granted to the reporting person on August 22, 2019. In exchange for the option, the reporting person received 1,600 stock options. F7 · derivative.exercise_date: This cancelled option vested in 18 equal monthly installments from August 22, 2019 to February 22, 2021. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 16:11 UTC | Tricida, Inc. TCDA · Entity 122050 | GrantEmployee Stock Option (right to buy) · Derivative | 3,959 | $0.00 Strike: $3.88 | $0.00 |
DisclosureSEC source: 0001595585-21-000109 · wf-form4_162931748837848.xml · derivative · entry 6 Yoshiyama Annie · CIK 0001835208 · VP, Finance and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,959 Underlying: Common Stock · 3,959 shares Expires 2028-08-15 F6 · price: On August 16, 2021, the issuer canceled, pursuant to the issuer's stock option exchange program, an option granted to the reporting person on February 20, 2019. In exchange for the option, the reporting person received two stock options in the amounts of 6,042 and 3,959. F4 · derivative.exercise_date: This option vests one-third on August 16, 2022 and the remaining two-thirds vests in 24 substantially equal monthly installments thereafter, subject to reporting person's continuous service as of each vesting date. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 16:11 UTC | Tricida, Inc. TCDA · Entity 122050 | GrantEmployee Stock Option (right to buy) · Derivative | 6,042 | $0.00 Strike: $3.88 | $0.00 |
DisclosureSEC source: 0001595585-21-000109 · wf-form4_162931748837848.xml · derivative · entry 5 Yoshiyama Annie · CIK 0001835208 · VP, Finance and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,042 Underlying: Common Stock · 6,042 shares Expires 2028-08-15 F6 · price: On August 16, 2021, the issuer canceled, pursuant to the issuer's stock option exchange program, an option granted to the reporting person on February 20, 2019. In exchange for the option, the reporting person received two stock options in the amounts of 6,042 and 3,959. F3 · derivative.exercise_date: This option vests on August 16, 2022. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 16:11 UTC | Tricida, Inc. TCDA · Entity 122050 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $22.82 | $0.00 |
DisclosureSEC source: 0001595585-21-000109 · wf-form4_162931748837848.xml · derivative · entry 4 Yoshiyama Annie · CIK 0001835208 · VP, Finance and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2029-02-19 F6 · price: On August 16, 2021, the issuer canceled, pursuant to the issuer's stock option exchange program, an option granted to the reporting person on February 20, 2019. In exchange for the option, the reporting person received two stock options in the amounts of 6,042 and 3,959. F5 · derivative.exercise_date: This cancelled option vested 25% on February 20, 2020, and the remaining 75% vests in 36 substantially equal monthly installments thereafter, subject to reporting person's continuous service as of each vesting date. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 16:11 UTC | Tricida, Inc. TCDA · Entity 122050 | GrantEmployee Stock Option (right to buy) · Derivative | 2,750 | $0.00 Strike: $3.88 | $0.00 |
DisclosureSEC source: 0001595585-21-000109 · wf-form4_162931748837848.xml · derivative · entry 3 Yoshiyama Annie · CIK 0001835208 · VP, Finance and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,750 Underlying: Common Stock · 2,750 shares Expires 2028-08-15 F2 · price: On August 16, 2021, the issuer canceled, pursuant to the issuer's stock option exchange program, an option granted to the reporting person on September 27, 2018. In exchange for the option, the reporting person received two stock options in the amounts of 9,251 and 2,750. F4 · derivative.exercise_date: This option vests one-third on August 16, 2022 and the remaining two-thirds vests in 24 substantially equal monthly installments thereafter, subject to reporting person's continuous service as of each vesting date. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 16:11 UTC | Tricida, Inc. TCDA · Entity 122050 | GrantEmployee Stock Option (right to buy) · Derivative | 9,251 | $0.00 Strike: $3.88 | $0.00 |
DisclosureSEC source: 0001595585-21-000109 · wf-form4_162931748837848.xml · derivative · entry 2 Yoshiyama Annie · CIK 0001835208 · VP, Finance and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,251 Underlying: Common Stock · 9,251 shares Expires 2028-08-15 F2 · price: On August 16, 2021, the issuer canceled, pursuant to the issuer's stock option exchange program, an option granted to the reporting person on September 27, 2018. In exchange for the option, the reporting person received two stock options in the amounts of 9,251 and 2,750. F3 · derivative.exercise_date: This option vests on August 16, 2022. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 16:11 UTC | Tricida, Inc. TCDA · Entity 122050 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $31.85 | $0.00 |
DisclosureSEC source: 0001595585-21-000109 · wf-form4_162931748837848.xml · derivative · entry 1 Yoshiyama Annie · CIK 0001835208 · VP, Finance and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2028-09-26 F2 · price: On August 16, 2021, the issuer canceled, pursuant to the issuer's stock option exchange program, an option granted to the reporting person on September 27, 2018. In exchange for the option, the reporting person received two stock options in the amounts of 9,251 and 2,750. F1 · derivative.exercise_date: This cancelled option vested 25% on September 27, 2019 and the remaining 75% vests in 36 substantially equal monthly installments thereafter, subject to reporting person's continuous service as of each vesting date. Read SEC document |
| January 17, 2021 Filed Jan 20, 2021 17:31 UTC | Tricida, Inc. TCDA · Entity 122050 | GrantEmployee Stock Option (right to buy) · Derivative | 70,980 | $0.00 Strike: $7.03 | $0.00 |
DisclosureSEC source: 0001595585-21-000030 · wf-form4_161118185148016.xml · derivative · entry 1 Yoshiyama Annie · CIK 0001835208 · VP, Finance and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,980 Underlying: Common Stock · 70,980 shares Expires 2031-01-16 F1 · derivative.exercise_date: The option to purchase common stock will vest as follows: (a) 25% of the shares subject to the options shall vest on January 17, 2022, and (b) the remaining 75% vest in 36 equal monthly installments thereafter, subject to reporting person's continuous service as of each vesting date. Read SEC document |
| December 04, 2020 Filed Dec 8, 2020 20:33 UTC | Tricida, Inc. TCDA · Entity 122050 | GrantEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $7.66 | $0.00 |
DisclosureSEC source: 0001595585-20-000151 · wf-form4_160747759303911.xml · derivative · entry 1 Yoshiyama Annie · CIK 0001835208 · VP, Finance and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-12-03 F1 · derivative.exercise_date: This option vests 25% on December 4, 2021, and the remaining 75% vests in 36 substantially equal monthly installments thereafter, subject to reporting person's continuous service as of each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.